Living Cell Technologies Limited (LCT) is an Australasian biotechnology company improving the wellbeing of people with serious diseases worldwide by discovering, developing and commercialising regenerative treatments which restore function using naturally occurring cells.



Our lead product, NTCELL®, is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells. After transplantation NTCELL functions as a biological factory, producing factors to promote new central nervous system growth and repair disease-induced nerve degeneration.



A Phase IIb trial of NTCELL for Parkinson's disease is currently underway. It aims to confirm the most effective dose of NTCELL, define any placebo component of the response and further identify the initial target Parkinson’s disease patient sub group. If the trial is successful LCT will apply for provisional consent to treat paying patients in New Zealand and launch NTCELL as the first disease modifying treatment for Parkinson’s disease, in 2017.


NTCELL Clinical Study results to be announced on Friday 10 November

Looks like the results are not statistically significant

http://www.lctglobal.com/upload/news...%20results.pdf

yep, pretty bad at 26weeks but they staggered treatments and have 9month data for 1 group which they didn't report. investor conf this evening at 7pm pst by my calculations




NTCELL Clinical Study results to be announced on Friday 10 November

Results of NTCELL® Clinical Study in Parkinson’s

Results released to ASX on Friday 10 November
Company to host conference call on Friday 10 November at 2:00pm AEST / 4:00pm NZT

LCT has announced a trading halt ahead of the announcement of the results of the Phase IIb clinical study of NTCELL in Parkinson's disease on Friday 10 November.

Investor call

LCT CEO Ken Taylor and Principal Investigator Dr Barry Snow will host an investor call to discuss the results of the Phase IIb clinical study of NTCELL in Parkinson's disease on the day of the announcement.

Date: Friday 10 November 2017
Time: NZT 4:00pm, AEST 2:00pm

Conference ID: 3389168

Toll-free dial-in numbers for participants:
Australia - 1800 123 296
New Zealand - 0800 452 782
Canada - 1855 5616 766
China - 4001 203 085
Hong - Kong 800 908 865
India - 1800 3010 6141
Japan - 0120 985 190
Singapore - 800 616 2288
United Kingdom - 0808 234 0757
United States - 1855 293 1544
or
toll +61 2 8038 5221

Here’s the link. Video was worth watching too

Living Cell Technologies Ltd shares rise on positive initial Parkinson’s disease study results

I'm not impressed by the results, very few patients and they didn't show the individual data. i assume they will be required to do a much larger trial in order to get this treatment approved in N.Z. and i think it will be more difficult finding volunteers if they have to wait a year or more to see fairly minor improvements. imho, if the results were that remarkable there would be some mention of this treatment and i've seen none outside of LCT. And imagine how hard it is to keep everything else constant for a year for each patient as they wait for some positive results to occur. one patient starting a vigorous exercise program might show equal improvement to the LCT treatment improvement. i also noticed they didn't mention quality of life measurements, just how much better did the patient feel? but what do i know? hope it turns out to be effective.